We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
PhoreMost and Oxford Biomedica have entered into a discovery collaboration to develop next-generation CAR-T cell therapies. Financial details of the agreement are not disclosed.
Oxford Biomedica has signed a Licence and Clinical Supply Agreement (LSA) with Bristol-Myers Squibb’s Juno Theraputics, granting the latter a non-exclusive license to the LentiVector platform.